Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 10, Issue 10, Pages 549-550Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2013.152
Keywords
-
Categories
Ask authors/readers for more resources
Two phase III trials have shown that prolonging chemotherapy duration improves outcome in patients with nonsquamous non-small-cell lung cancer. Pemetrexed versus placebo, and pemetrexed-bevacizumab versus bevacizumab was tested in patients without disease progression after pemetrexed-cisplatin treatment. Biomarker-directed chemotherapy and/or targeted therapy could further improve treatment outcomes for patients with lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
